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manufacturers. There are several options for remedy such as a more comprehensive 
product review programme, but this could lead to further delays.
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Objectives: Since the health care reform in Germany (AMNOG) in 2011, newly 
approved drugs have to demonstrate their innovation to avoid reference group 
pricing. The pharmaceutical manufacturer (PM) has to submit a dossier proving 
additional benefit versus the appropriate comparator recommended by the G-BA 
(Joint Federal Committee). MethOds: Benefit assessments and G-BA decisions 
to date were analyzed. Outcome data, indirect comparisons and decisions (until 
January 2015) were explored with regard to factors potentially impacting the out-
come of price negotiations. Results: 148 agents entered the assessment process, 
102 dossier completed the whole assessment process. G-BA evaluations resulted 
in 26 minor, 21 considerable, and 55 not quantifiable/no additional therapeutic 
benefit of assessed vs. comparator drug. In 29 cases the G-BA did not follow IQWiG’s 
conclusions of the extent of additional benefit. The choice of appropriate com-
parator was controversial between G-BA and PM in 10 cases, followed by questions 
about evidence of benefit. 5 drugs, which failed to prove an additional benefit, were 
withdrawn from the German market. In a sub-analysis 18 drugs were examined, 
where the reimbursed price has been negotiated between the National Association 
of Statutory Health Insurance Funds (GKV-SV) and PM. The mean rebate was 17% 
with a range from 0 to 52%. Negotiated rebates were not correlated with any of the 
clinical and economic parameters (e.g. number of patients benefitting, proposed 
price) analyzed. cOnclusiOns: AMNOG mediates price control despite mandatory 
reimbursement of innovative drugs. Following initial pitfalls in dossier develop-
ment the withdrawal of 5 drugs in 2012 may indicate that nowadays either the PMs 
are more familiar with AMNOG or, that drugs with limited potential of proving an 
additional benefit tend to be not launched in Germany. The majority of price nego-
tiations resulted in reductions of < 20%. It was not possible to identify parameters 
predicting the magnitude of rebates.
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Objectives: Early market access schemes are expanding across the globe, pre-
senting health technology suppliers with a variety of opportunities for expediting 
product approval. This paper aims to provide an overview of three such schemes: 
the ‘conditional approval’ opportunity in Japan’s Pharmaceuticals, Medical Devices 
and Other Therapeutic Products (PMD) Act; the UK’s Early Access to Medicines 
Scheme (EAMS); and the Breakthrough Therapy (BT) designation program in 
the US. MethOds: Secondary research identified market-specific early access 
schemes and key themes were evaluated. Where available, quantitative data were 
analyzed. Hypotheses were generated and then validated during in-depth inter-
views with key stakeholders across markets. Results: The US BT designation 
is the most advanced early access opportunity, having been established in July 
2012. Of the 212 technologies reviewed so far, 35% have gained BT status. Through 
December 2014, 16 have subsequently obtained full approval. Launched in the 
UK in April 2014, the EAMS has had three promising innovative medicine (PIM) 
designations, which forms the first of two steps in gaining early market access. In 
Japan, the conditional approval scheme focuses on regenerative medicines and, 
while interest is significant, the program is in its infancy, having been formalized 
in November 2014. cOnclusiOns: Health technology suppliers need to evaluate 
associated costs and benefits when determining whether any of the early access 
routes are appropriate for a novel product. One consideration is the type of tech-
nology in scope: developers of regenerative cell therapies should consider the 
Japanese scheme, but will need to leverage local partnerships in order to facilitate 
access. Another consideration is the costs involved in application, and whether the 
technology is reimbursed during the program. While products are reimbursed in 
Japan, UK reimbursement is not guaranteed. The BT program is the most mature 
and globally recognized of the three, and offers ongoing regulatory support until 
final marketing authorization.
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Objectives: HTA agencies in both Germany (IQWiG) and France (TC) focus on 
additional benefits without explicit consideration of cost in their HTA assessment. 
While the German Federal Joint Committee (GBA) usually commissions IQWiG for 
the assessment, the GBA makes final decisions on the level of additional benefit 
provided by a new therapy. We sought to document whether the GBA and TC 
reached the same rankings for the same drug indication evaluated. MethOds: 
We first searched GBA assessments conducted from August 2011 to July 2014 and 
then cross checked whether the TC completed its own assessment for the same 
indication. The GBA classifies additional benefits as “Major, Considerable, Minor, 
Non-quantifiable, No Benefit, and Less Benefit”. For the TC, they are categorized as 
“Major, Important, Significant, Minor, No Improvement, Do Not Recommend”. We 
also examined the comparators used in the assessments. Results: A total of 67 
indications were evaluated by both agencies. No indication was awarded “Major” 
by either agency. For 17 “Considerable” ranking granted by the GBA, 2 were given 
“Important”, 8 “Significant”, 6 “Minor”, and 1 “No Improvement” by the TC. For 21 
“Minor” ranking awarded by the GBA, 1 was considered “Significant”, 11 “Minor”, 
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Objectives: Under the positive drug listing system, pharmaceutical companies in 
Korea are required to provide cost-effectiveness (CE) evidence of newly approved 
drugs for listing on the National Health Insurance (NHI) drug formulary. It has been 
argued that selection criteria of comparator treatments suggested by the CE guide-
line are too limited and unrealistic to conduct a valid CE assessment. Therefore, 
our study was conducted to investigate types of practical problems in comparator 
selection in order to improve the validity of CE analysis. MethOds: We conducted 
focus group interviews (FGI) with experts working in research-based drug compa-
nies, charged of submitting CE evidence of their products to NHI. Each participant 
received an interview question via an e-mail beforehand and presented their opin-
ions at round-table discussion. Results: Examples of the problems associated with 
selecting appropriate comparators identified from FGI are as follows: drugs with 
the same indication, but therapeutically nonequivalent, were used as comparators ; 
there is no guidance on whether to include off-label drugs as comparators; when off-
patent products were selected as comparators, the price of the new drug was com-
pared with the price of generic products rather than the initial price of the original 
products set during the patent period; it is difficult to obtain reliable market share 
data needed for selecting a comparator; and the best supportive care was selected as 
a comparator when there’s no appropriate treatment alternatives. cOnclusiOns: 
We expect that the results of our investigation would contribute to improve the 
quality of CE guidelines in South Korea as well as other countries, and to improve 
assessment of the true value of pharmaceutical intervention.
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Objectives: To establish a working definition of “quality” in the HTA context; to 
identify the key features of good-quality HTA submission and review performance. 
The outcome of the research will be used to facilitate the development and adoption 
of best practices in HTA submissions, assessment processes and decision mak-
ing. MethOds: The research was initiated by identifying common elements that 
underpin a quality submission dossier, and a set of key performance indicators 
(KPIs) of HTA review processes and procedures. International experts representing 
HTA/coverage agencies, academics and pharmaceutical companies were invited 
to discuss the identified parameters from diverse viewpoints. The key discussion 
points and recommendations for KPIs are outlined herein. Results: Four elements 
of a quality dossier were identified: robustness and relevance of the scientific data; 
dossier completeness, that is, the inclusion of all relevant information; integrity or 
consistency; and logical structure and clear format. Quality of HTA review is most 
easily measured by assessing outcomes of tools designed to ensure or to support 
good-quality process such as internal and external peer reviews, audits, standard 
operating procedures and procedures for learning and feedback. Ten KPIs of the HTA 
review process considered important from a company’s perspective were identified 
as well the four main areas from HTA agencies perspective: timeliness, relevance, 
credibility and impact. cOnclusiOns: A key outcome of this research was a clear 
understanding of “quality” in the context of HTA across stakeholders, and the iden-
tification of key factors, irrespective of the diversity of HTA agencies, which could 
be used to measure the quality of process. The next phase of the research will be to 
develop an instrument to measure quality of HTA process based on identified KPIs 
and to be piloted and validated by key stakeholders.
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Objectives: In contrast to the Scottish Medicines Consortium, NICE does not 
evaluate all new medicines, but uses a set of specific selection criteria. Where a 
technology is not selected for assessment the affected products may face difficul-
ties in achieving payer and physician uptake. We aim to demonstrate and evaluate 
the difficulties faced by those seeking market access for products and the conse-
quence of non-selection. Whilst oncology products currently have the Cancer Drugs 
Fund (CDF) to fall back on, there is an issue of how NICE, CDF and NHS England 
policies will work together in the future. We further consider the possible options, 
both for delaying and non-assessment, or failure to obtain reimbursement through 
other routes. MethOds: We review the topic selection methodologies and com-
pare the number of marketing authorizations approved in recent years and those 
products reviewed by NICE. Examples of orphan drugs that have not been selected 
are provided. We further review opportunities for redress for the manufacturer 
where they are not subject to a technology appraisal. Results: The position of a 
company seeking reimbursement for a new product that has not been reviewed 
by NICE is precarious, forcing them to rely on NHS England policies, local com-
missioner approvals, individual hospitals within CCGs or, ultimately, legal redress. 
Currently, there are over 20 NHS England policies to support the commissioning 
of products, and services associated with those products; and over 100 awaiting 
review. The common characteristic accompanying success is strong clinical support 
from the relevant NHS England clinical reference group and powerful patient lob-
bying. cOnclusiOns: The current position, whether caused by delay or a positive 
decision by NICE not to review, is considered unsatisfactory both for patients and 
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hematology(n= 62), dermatology(n= 14) and psychiatry(n= 72), others(n= 3) from 
outpatient and inpatient care. The survey consisted of qualitative and quantita-
tive questions covering areas such as the most trusted sources of RWE in Poland, 
pharma role in RWE generation vs. government’s contribution, most desired type 
of RWE. The questionnaires were collected Sept-Nov 2014 (the total number of 
responses received n= 251). Data were analyzed using simple descriptive statis-
tics. Results: Physicians demonstrated high degree of interest in evidence on 
practical outcomes, particularly in data on safety and effectiveness of treatment 
(over 90% of responders); at the same time 1 out of 5 doctors claimed that data 
on effectiveness are hardly accessible in Poland. Interesting differences regarding 
desired real life data were observed across specialties: i.e. treatment pathways and 
prescribing patterns were frequently valued by diabetologists (87%), while quality 
of life was often quoted by hematologists (87%). For psychiatrists (69%) data on 
direct treatment costs are highly important whereas data on patient compliance 
was most often mentioned by oncologists (79%). cOnclusiOns: The research 
showed high physicians’ interest in practical evidence and the variety of RWE 
perception. The differences in priorities between specializations indicate unmet 
needs in therapeutic areas. Broadening doctor’s and other stakeholders knowledge 
in RWE data significance and improving its accessibility could be crucial for gain-
ing doctor’s advocacy for shaping RWE landscape in Poland and, consequently, for 
improving patient’s treatment results.
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Objectives: There is limited evidence of the association between spatial segre-
gation by income and health outcomes worldwide. Our objective was to deter-
mine crude and adjusted associations between self-reported disability and four 
measures of spatial segregation by income at individual, household, borough, and 
health service level in Chile. MethOds: Secondary analysis of representative, 
anonymous CASEN 2009 survey (n= 105,508 of > 20 years age participants from 
45,021 households/ 315 boroughs/ 29 health services). The relationship between 
self-reported disability (physical, sensorial, psychiatric/cognitive) and spatial 
segregation by income (isolation index, dissimilarity index, Jargowsky coeffi-
cient) was explored using 4-level multilevel logistic regression. Control variables 
were health service´s income inequality (GINI coefficient), age, sex, equivalized 
household income and educational level. The analysis was stratified by house-
hold material poverty (as defined in 2009; around USD$130 per month). Results: 
Individuals living below the poverty line showed a positive association between 
spatial isolation and overall and sensorial self-reported disability. However, there 
was a protective association between spatial isolation and psychiatric/cognitive 
self-reported disability. Otherwise, people living above the poverty line, showed 
a positive association between spatial isolation and overall, physical, sensorial 
and indeed psychiatric/cognitive self-reported disability. Dissimilarity index and 
Jargowsky coefficient did not show any significant association. Besides, equival-
ized household income, education, sex and age were important factors associ-
ated with self-reported disability, but not for income inequality. cOnclusiOns: 
Some measures of spatial segregation (isolation) were associated with self-
reported disability, even after adjusting for health service´s income inequality 
and individual-level socio-demographics. These associations may differ depend-
ing on the presence of absolute poverty and, hence, further research is urgently 
required.
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Objectives: Multiple chronic conditions (MCCs) are related to increased health 
care services and cost and decreased quality of life. Due to the broad implications 
of MCCs and Body Mass Index (BMI) for Health Policy, this study evaluated the 
relation between MCCs and BMI through population estimates, accounting for 
demographic characteristics and risk factors. MethOds: Data from the cross-
sectional telephone survey Behavioral Risk Factor Surveillance System, for years 
2011 and 2013 (N= 12,624), was used to obtain the self-reported count of chronic 
conditions (CCs) and BMI. This study included adults 18 years or older living in 
Puerto Rico with 1 to 6 diagnoses of CCs, and with BMI (kg/m^2) between 20.0 and 
45.99. Females that reported pregnancy at time of survey were excluded from 
analysis. Survey-weighted summary statistics were estimated and Poisson regres-
sion coefficients and standard errors (S.E.) calculated using generalized linear 
models in R. Results: The study population (n= 7,830) represented approximately 
1,462,598 adults (55.9%, 95% confidence interval [C.I].: 54.7-57.0). The estimated 
MCCs prevalence was 56.1% (95% C.I.: 54.7-57.0), whereas the BMI mean was 28.7 
kg/m^2 (S.E= 0.08). After adjusting by age, gender, income, smoking status, binge 
drinking, and high cholesterol the regression model showed that the possibil-
ity of reporting more than one chronic condition increases 2.0% (S.E. = 0.16%) 
with an increment in a BMI unit. The most prevalent combinations of two and 
three chronic conditions were arthritis-hypertension (10.7%, 95% C.I.: 9.7-11.7), 
and diabetes-arthritis-hypertension (5.4%, 95% C.I.: 4.7-6.1). cOnclusiOns: 
Study results suggested that in adults living in Puerto Rico with a chronic con-
dition, the possibility of reporting an additional chronic condition increases as 
BMI increases. Decision makers should use these findings to support popula-
tion interventions for weight reduction, policy evaluation, and development of 
MCC guidelines in an effort to improve quality of life and decrease health care 
spending.
and 9 “No Improvement” by the TC. For 22 “No Benefit” judged by the GBA, 21 
were determined “No Improvement” and 1 “Do Not Recommend” by the TC. Of the 
26 anti-cancer indications evaluated, similar patterns were observed. Regarding 
comparators, the TC tended to list multiple whereas the GBA usually used one. 
In 12 assessments (18%), a completely different comparator was used by the two 
agencies. cOnclusiOns: While German and French HTA agencies had similar 
HTA evaluations for a majority of assessments, some differences were noted. 
Notably, the TC tended to be more restrictive and apply multiple comparators in 
its HTA evaluations.
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Objectives: The Scottish Medicines Consortium (SMC) requires all manufactures 
to submit clinical and economic evidence for products no later than 3 months 
after licensing. Any products without a submission are automatically not rec-
ommended. Due to the complexity of the UK market access environment, small 
or medium pharmaceutical enterprises (SMEs) may not have the knowledge or 
resource to generate submissions for all products. In 2015, the SMC aim to improve 
early engagement with SMEs. To establish the importance of this engagement, 
we assess the differences in submissions and recommendations between SMEs 
and larger companies. MethOds: Categorizing the top 30 pharmaceutical com-
panies (based on gross revenue) of 2013 as large companies and all other sub-
mitting companies as SMEs, SMC recommendations following full, abbreviated 
or resubmissions were analyzed along with the proportion of non-submissions. 
Recommendations for co-marketed products were divided evenly between manu-
facturers. Results: There is a statistically significant relationship between the 
proportion of positive guidance for large companies and SMEs (75.47% versus 
64.62%, p= 0.0002). The number of non-submissions from large companies was 
14 in 2012, 18 in 2013 and 8 in 2014; from SMEs the number of non-submissions 
was 11 in 2012, 7 in 2013 and 6 in 2014. cOnclusiOns: There is a relationship 
between company size, based on revenue, and likelihood of a positive SMC recom-
mendation, but identification of the cause and effect requires further analysis. 
These results could indicate that large pharmaceutical companies have a greater 
influence on the decisions of the SMC, or simply more experience and resource 
to increase the chances of success. In 2014, the 30 largest companies accounted 
for more non-submissions than all other pharmaceutical companies, suggesting 
that large companies can afford to pick and choose whether to submit to the SMC 
or gain reimbursement through alternative channels whilst avoiding the wider 
impact of negative guidance.
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Objectives: Medical Apps nowadays play a pivotal role in managing individuals 
in health and wellness Management and subsequently also useful to the health-
care professionals. The existing studies or results emphasize only on benefits of 
smartphones or usage of medical apps. Present study aims to evaluate the medi-
cal apps and the promotional strategies adopted by the developers to enhance 
app downloads and ratings. MethOds: 150 medical and healthcare Android 
Apps were randomly selected from India and other countries including USA, UK, 
Australia. These apps were evaluated with regard to number of downloads, critical 
reviews by the user, rater’s rating, rating by the users and app content by using the 
data collection form. The promotional strategies adopted by these app developers 
were also studied. SPSS 15.0 was used to statistically analyze the data. Chi square 
test was applied to assess association between the number of downloads and 
various promotional strategies adopted (P< 0.05). Mann-Whitney test was used 
to find the promotional strategies resulting in to Five Star ratings. Results: 
The study revealed that there are no stringent regulations and guidelines with 
respect to medical apps in India. Whereas various parameters were extensively 
used in countries such as USA, Australia and EU like usage of HD images, sugges-
tive/awareness, specificity of the disease which aren’t so regular with respect to 
Indian app developers. There was a significant association between downloads 
and promotional strategies such as google search, websites, social media, review 
ratings. cOnclusiOns: This study clearly suggests the promotional strategies 
which can be adopted by the existing and new app developers to have high down-
load success rates. Hence study is highly useful to start ups and existing small 
entrepreneurs.
HeAltH cAre use & Policy studies – Patient registries & Post-marketing 
studies
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Objectives: Real World Evidence (RWE) is likely to become increasingly impor-
tant in decisions that affect patient’s access to medicines worldwide. However, 
absence of long-term patient registries and electronic documentation consti-
tute the greatest barriers for generating RWE studies in Poland. Therefore, an 
exploratory survey was undertaken to map current awareness and expectations 
of physicians related to practical outcomes data and to identify pharmaceuti-
cal industry’s role in RWE generation. MethOds: The study was conducted 
across 6 doctors’ specialties: diabetology(n= 30), virology(n= 42), oncology(n= 28), 
